The influence of insulin resistance on therapeutic response in newly diagnosed patients with multiple myeloma
Authors:
- Nada VlaisavljevićNVNada Vlaisavljević
- Ivana UroševićIUIvana Urošević
- Dragana Tomić-NaglićDTDragana Tomić-Naglić
Open Access
- 1 January 2024
- journal article
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Srpski medicinski casopis Lekarske komore
- Vol. 5 (3) , 331-340
Abstract
Introduction: According to the results of previous research, it was found that the dysfunction of the insulin-like growth factor (IGF) system, which is the basis of insulin resistance with hyperinsulinemia, acts as a proliferative tumor factor, and its neoplastic potential is also exhibited in multiple myeloma. Study aim: The study aims to determine whether there is an association between insulin resistance in patients newly diagnosed with multiple myeloma (NDMM) and the achieved therapeutic response after induction chemotherapy. Materials and methods: The prospective study included 35 NDMM patients (60% women and 40% men), treated at the Clinical Center of Vojvodina Clinic for Hematology. Glycemia and insulinemia levels were determined after fasting and postprandially, upon which the values of HOMA-IRIf (after fasting) and HOMA-IRIpp (postprandially) were calculated. HOMA-IRI values > 2.2 were the criteria for insulin resistance. The analyses were performed twice - before the initial chemotherapy and after the completion of the treatment. The therapeutic response was evaluated according to the criteria of the Serbian Myeloma Group (SMG) and the International Myeloma Working Group IMWG). Statistical analyses were performed in the SPSS program, Version 22. Results: The average patient age was 63.85 years. In total, 86% of patients responded favorably to the therapy. The average value of HOMA-IRIf before treatment was 1.82 ± 0.79 and it was 1.80 ± 0.72 after therapy. The central median value of HOMA-IRIpp before treatment was 5.46, with an interquartile range of 1.07 - 20.57, and after treatment, it was 5.86 with an interquartile range of 1.22 - 28.22. A significant negative correlation between HOMA-IRIf after applied treatment and achieved therapeutic response was observed, (p = 0.040). Conclusion: Active concomitant therapy of insulin resistance in NDMM could improve the response to applied antimyeloma treatment.Keywords
This publication has 19 references indexed in Scilit:
- Metformin Inhibits Multiple Myeloma Serum-induced Endothelial Cell Thrombosis by Down-Regulating miR-532Annals of Vascular Surgery, 2022
- Reduced Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma in Type 2 Diabetes Mellitus: Will Metformin Never Stop Its Pleasant Surprises?Advances in Therapy, 2022
- The insulin-like growth factor system: A target for endocrine disruptors?Environment International, 2021
- Response Assessment in Myeloma: Practical Manual on Consistent Reporting in an Era of Dramatic Therapeutic AdvancesTransplantation and Cellular Therapy, 2017
- Impact of metformin on the progression of MGUS to multiple myelomaLeukemia & Lymphoma, 2016
- IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing SarcomaJNCI: Journal of the National Cancer Institute, 2016
- Metformin and cancer therapyCurrent Opinion in Oncology, 2012
- Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activationLeukemia, 2010
- Homeostatic model assessment (HOMA) index cut-off values to identify the metabolic syndrome in childrenJournal of Physiology and Biochemistry, 2005
- Treatment of insulin resistance in diabetes mellitusEuropean Journal of Pharmacology, 2004